



ELSEVIER

Prostaglandins & other Lipid Mediators 71 (2003) 301

**PROSTAGLANDINS
& other
LIPID MEDIATORS**

Author Index

- Accomazzo, M.R., 235
Akamaru, S., 253

Beck-Speier, I., 217
Bishop-Bailey, D., 1
Brietbart, H., 119
Brock, T.G., 131

Capra, V., 235
Celotti, F., 147
Chang, W.-C., 277
Coffey, M.J., 131

Dayal, N., 217
Denzlinger, C., 217
Durand, T., 147

Elder, M.G., 43
Enrico Rovati, G., 235
Eynard, A.R., 177

Fang, X., 33

Haberl, C., 217
Hatakeyama, M., 293
Heyd, V.L., 177
Heyder, J., 217
Honn, K.V., 189
Humphreys, V., 55

Imaizumi, T., 293
Ito, H., 253

Jabbour, H.N., 97
Jain, N.K., 163

Kandouz, M., 189
Katsube, N., 253
Kawakami, Y., 205
Kim, L., 55
Kock, J.L.F., 85
Krishnamoorthy, S., 189
Kulkarni, S.K., 163
Kumagai, M., 293

López Bernal, A., 23

Macchia, M., 235
Maddipati, K.R., 189
Maegawa, H., 253
Maier, K.L., 217
Mancuso, P., 131
Marsala, M., 253
Maru, E., 205
McNish, R.W., 131
Meves, H., 265
Michaeli, S., 119
Moore, F., 23

Nakai, K., 253
Nicosia, S., 235
Nie, D., 189
Nigam, S., 85

Parenti, M., 235
Patil, C.S., 163
Peters-Golden, M., 131
Pidgion, G.P., 189
Pohl, C.H., 85

Raisz, L.G., 287
Ravasi, S., 235

Sales, K.J., 97
Satoh, K., 293
Shemesh, M., 119
Shore, L., 119
Singh, A., 163
Singh, V.P., 163
Spector, A.A., 33
Stram, Y., 119
Strauss, C.J., 85
Sugiura, H., 205
Sullivan, M.H.F., 43
Suzuki, K., 205

Takemiya, T., 205
Takenobu, Y., 253
Takimizu, H., 253
Tamo, W., 293
Tanji, K., 293
Tsuda, V., 55

Weems, C.W., 55
Weems, Y.S., 55
Weintraub, N.L., 33
Woodiel, F.N., 287
Wray, J., 1

Xiuzhu, T., 119

Yamagata, K., 205
Yamashita, K., 293
Yasuda, S., 205
Yoshida, H., 293

Ziesenis, A., 217
Zosmer, A., 43





ELSEVIER

Prostaglandins & other Lipid Mediators 71 (2003) 303

**PROSTAGLANDINS
& other
LIPID MEDIATORS**

Subject Index

- Agonists, 287
Anti-inflammatory drugs, 147
Anti-tumour activities, 177
Arachidonic acid, 43, 55, 189
- Bone formation, 287
Bone resorption, 287
Bovine aortic endothelial cells, 119
Brain COX-2, 205
- cAMP, 265
Caspase 3, 23
Cilostazol, 253
c-Jun, 277
COX-1, 147
COX-2, 147
COX inhibitors, 147
Cyclooxygenase, 1, 97, 131, 147, 217
Cyclooxygenase II, 119
CysLT₁ receptors, 235
Cytochrome P450, 1
- Dibutyl cAMP, 43
15d-PGJ₂, 293
- Eicosanoids, 189
Eicosatrienoic acid, 177
Endothelial cells, 293
Endothelium, 33
Epidermal growth factor, 277
Epoxyeicosatrienoic acid, 33
Epoxygenase, 1
Esterification, 3
- Fatty acids, 1, 177
Fungi, 85
- Gene activation, 277
Gene silencing, 119
GM-CSF, 293
- 12(S)-HETE, 189
Hippocampal seizures, 205
Human 12(S)-lipoxygenase, 277
Human cancer cell lines, 177
Human uterine smooth muscle, 23
3-Hydroxy oxylipin, 85
- Inflammatory bowel disease, 163
Intermittent claudication, 253
- Leukotrienes, 131
Licofelone, 147
Lipids, 1
Lipopolysaccharide, 131
Lipoxygenase, 1, 217
5-Lipoxygenase, 131, 147
12-Lipoxygenase (12-LOX), 189
5-LOX, 147
LOX inhibitors, 147
LTD₄, 235
Luteinizing hormone, 55
- Macrophages, 217
- NF- κ B, 189
NG108-15 cells, 265
Nimesulide, 163
Nitric oxide synthase, 131
Non-selective cation channel, 265
OP-1206 α -CD, 253
- PAF, 217
Peritoneal macrophage, 131
Peroxisome proliferator-activated receptor, 1
PGE₂, 205
Phorbol ester, 277
Phospholipase A₂, 217
Phospholipid, 33
Prenylated proteins, 235
Progesterone, 55
Prostaglandin, 97
Prostaglandin E₁, 265
Prostaglandin E₂, 287
Prostanoids, 163
Prostate cancer, 189
Protein expression, 23
- Rapid kindling, 205
Receptors, 97
Reproductive pathology, 97
RhoA-associated protein kinase I, 23
- Signal transduction, 235
Smooth muscle, 33
Sp1, 277
Spinal canal stenosis, 253
Spinal cord blood flow, 253
Sulfite, 217
- Thromboxane A₂, 23
Trophoblast, 43
- U46619, 23
U937 cells, 235
- Yeast, 85

1. The first part of the report is a general introduction to the subject of the study.

2. The second part of the report is a detailed description of the methods used in the study.

3. The third part of the report is a discussion of the results of the study.

